Evidence map›Paper›PMID 38116495›Full record

ArticleCase reports in rheumatology2023

A Case Report of Anti-TIF1-

Hiroyuki Hounoki, Takafumi Onose, Miho Yamazaki, Ryoko Asano, Satoshi Yamaguchi, Koichiro Shinoda, Kazuyuki Tobe, Akira Noguchi, Kenichi Hirabayashi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hiroyuki HounokiFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.ORCID https://orcid.org/0009-0008-8019-383X
Takafumi OnoseFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Miho YamazakiFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Ryoko AsanoFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Satoshi YamaguchiFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Koichiro ShinodaFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Kazuyuki TobeFirst Department of Internal Medicine, University of Toyama, Toyama, Japan.
Akira NoguchiDepartment of Diagnostic Pathology, University of Toyama, Toyama, Japan.
Kenichi HirabayashiDepartment of Diagnostic Pathology, University of Toyama, Toyama, Japan.
University of Toyama · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell neuroendocrine carcinoma is rare among urinary bladder cancer types, and to date, there are no case reports of concurrent antitranscriptional intermediary factor 1-

Identifiers

PMID38116495
PMCPMC10730251
OpenAlexW4389627146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.